logo
Baird Upgrades nCino (NCNO) to Outperform, Sees 29%

Baird Upgrades nCino (NCNO) to Outperform, Sees 29%

Shares of nCino (NCNO), a global provider of cloud-based software solutions in the financial services industry, are gaining momentum after an upgrade from Baird. Five-star analyst Joseph Vruwink raised the firm's rating from Neutral to Outperform and lifted the price target to $38 from $30. That implies a potential upside of about 29% from the stock's recent price of $29. Vruwink cited improved macro conditions, new product traction, and go-to-market execution as reasons for a more constructive view.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with , delivered to your inbox every week.
Confidence Returns as nCino Resets and Rebounds
According to Baird, management appears increasingly confident, following a financial reset earlier this year that reset investor expectations. The analyst believes nCino could deliver earnings beats in the coming quarters and sees the current setup as one of the best in years. Management meetings also highlighted stronger internal execution and increased enthusiasm around product updates.
Vruwink's bullish sentiment comes as a respite for nCino, which has had a tough year, down 12% year-to-date. Most of the decline occurred in March, following the company's reset of its financial outlook for fiscal 2026. Since then, the stock has bounced back and now trades within 5% to 10% of its pre-reset levels. Vruwink believes nCino is in the early stages of regaining investor confidence. The firm expects subscription growth to return to double digits and management to reach its goal of achieving the Rule of 40, which combines profit margin and revenue growth.
While the stock still faces hurdles, including cautious sentiment across small-cap software names, Baird sees a favorable risk-reward at current levels. For now, the market will be watching for signs that nCino can deliver consistent execution and meet its growth targets.
Is nCino a Good Stock to Buy?
On the Street, analysts are split over nCino, as it is rated Moderate Buy based on 17 analyst reviews, with 7 Buy and 10 Hold ratings. The average Wall Street price target is $31.38, indicating a 5% upside. No analysts currently rate the stock a Sell.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bank of America Securities Sticks to Its Hold Rating for nCino (NCNO)
Bank of America Securities Sticks to Its Hold Rating for nCino (NCNO)

Business Insider

time2 days ago

  • Business Insider

Bank of America Securities Sticks to Its Hold Rating for nCino (NCNO)

Bank of America Securities analyst Koji Ikeda reiterated a Hold rating on nCino on July 18 and set a price target of $34.00. The company's shares closed last Friday at $30.61. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Ikeda covers the Technology sector, focusing on stocks such as Datadog, nCino, and Gitlab. According to TipRanks, Ikeda has an average return of 12.6% and a 59.05% success rate on recommended stocks. In addition to Bank of America Securities, nCino also received a Hold from TR | OpenAI – 4o's Ivy Interfayce in a report issued on July 18. However, on July 14, Robert W. Baird upgraded nCino (NASDAQ: NCNO) to a Buy. NCNO market cap is currently $3.55B and has a P/E ratio of -120.42. Based on the recent corporate insider activity of 87 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NCNO in relation to earlier this year. Last month, Spencer Lake, a Director at NCNO sold 7,119.00 shares for a total of $184,828.66.

Tesla (TSLA) Faces Analyst Caution Ahead of Earnings as Risks Loom
Tesla (TSLA) Faces Analyst Caution Ahead of Earnings as Risks Loom

Yahoo

time3 days ago

  • Yahoo

Tesla (TSLA) Faces Analyst Caution Ahead of Earnings as Risks Loom

Tesla, Inc. (NASDAQ:) is one of the On July 16, Baird reiterated the stock as 'Neutral,' stating that it's cautious on Tesla ahead of earnings next week. 'We see risk to estimates stemming from both 1) full-year volume outlook and 2) potential margin compression in the Energy segment.' In other news, Evercore ISI reiterated the stock as in line on July 15th. The firm said it's staying cautious on Tesla shares. 'We believe the stock, today, is increasingly both NOISE & SIGNAL based on: 1) Unabated negative revisions, 2) Disappointing AV rollout, 3) Increasingly divisive political posting, & 4) Technicals on edge.' david-von-diemar-ZBWn5DvO0hg-unsplash Tesla, Inc. (NASDAQ:TSLA) is an automotive and clean energy company that leverages advanced artificial intelligence in its autonomous driving technology and robotics initiatives. While we acknowledge the potential of TSLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.

Sarepta downgraded to Neutral from Outperform at Baird
Sarepta downgraded to Neutral from Outperform at Baird

Business Insider

time4 days ago

  • Business Insider

Sarepta downgraded to Neutral from Outperform at Baird

Baird downgraded Sarepta (SRPT) to Neutral from Outperform with a price target of $15, down from $35. The firm sees 'broad, existential uncertainty' due to management transparency issues and questions around Elevidys remaining on the market. Following reports of the FDA asking Sarepta to stop shipments of Elevidys, the risk of the drug being removed from the market are 'greatly amplified,' the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store